Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Hypersplenism
Conditions: Unresectable Hepatocellular Carcinoma Interventions: Combination Product: Splenectomy+Targeted therapy+ Immunotherapy Sponsors: Zhiyong Huang; Wuhan Union Hospital, China; Wuhan University; Renmin Hospital of Wuhan University; Taihe Hospital; Hubei Cancer Hospital; Xiangyang Central Hospital of Hubei Province; Wuhan Central Hospital; The Third People ' s Hospital of Yichang City Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | China Health | COVID-19 | Hepatocellular Carcinoma | Hospitals | Immunotherapy | Liver Cancer | Research | Splenectomy